On October 2, 2018 AskAt Inc. (AskAt) (Headquarters: Nagoya, Japan, CEO: Akihiro Furuta) reported that Arrys Therapeutics, Inc. (Headquarters: Cambridge, Massachusetts), which licensed AAT-007 in immuno-oncology from AskAt in December 2017, has initiated a clinical study with AAT-007 (grapiprant) (ARY-007) in combination with pembrolizumab (anti PD-1 antibody, KEYTRUDA) (Press release, AskAt, OCT 2, 2018, View Source [SID1234535044]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study is an Open-label, Single-arm, Phase 1b clinical trial to evaluate the safety and efficacy of grapiprant in combination with pembrolizumab in patients with advanced or progressive Microsatellite Stable (MSS) Colorectal Cancer (CRC).

Arrys is the sponsor of the study, in collaboration with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.